Accurate identification of viable myocardium is crucial in patient qualification for medical or surgical treatment. Only persons with confirmed cardiac viability will benefit from revascularization procedures. It is also well known, that the amount of viable myocardium assessed preoperatively is the best indicator of long term cardiac event free survival after cardiac intervention. 
Background
Accurate identification of viable myocardium is crucial in patient qualification for medical or surgical treatment. Only persons with confirmed cardiac viability will benefit from revascularization procedures. On the other hand, in patients with preserved myocardial viability treated medically the annual cardiac death rate increases significantly-up to 16% versus 3.2% in the group after revascularization. A meta-analysis [1] showed 80% reduction in mortality if such patients had an interventional, revascularization treatment. It is also well known, that the amount of viable myocardium assessed preoperatively is the best indicator of long term cardiac event free survival after cardiac intervention [2] . Patients with no signs of viable myocardium should not be subjected to the risks of invasive surgery, because they don't have areas of myocardium that will show improved function after revascularization. According to the results of Allman's meta-analysis there is no significant difference noted between medical therapy and revascularization if patients had primarily nonviable myocardium (7.7% vs 6.2%) [1] . There are also data demonstrating that after revascularization, even in presence of myocardial viability, the clinically significant improvement in global left ventricular function is noted only in patients with relatively large areas of hibernated tissue -> 17% of the left ventricular mass [3] . The study is relatively long, the good patient's cooperation is necessary (for example the breath holding). The comparison studies demonstrated similar accuracy of CT and CMR [5] . The limitation of cardiac CT include low temporary resolution -which is improving but yet still limiting functional studies.
Małgorzata

Cardiac CT
Cardiac molecular imaging techniques
Both SPECT and PET techniques allow for the identification of ischemic but viable myocardium, analyzing myocardial perfusion and function (in gated exams). PET may also be used to evaluate myocardial metabolism. The thallium redistribution SPECT studies present 201Tl uptake depending on cell membrane integrity and thus myocyte viability. Additionally, the initial uptake of radiopharmaceutical shows the regional perfusion, allowing for thallium stress perfusion study, and assessment of coronary perfusion reserve. The sensitivity of the test is high (88%), although the meta-analysis has shown that the test may overestimate the viability (specificity of 49%) [2] .
Over the last years FDG PET was the gold standard for myocar- 
Physiologic cardiac metabolism
Normal cardiac muscle is able to produce energy from different substrates: free fatty acids (FFA), glucose and pyruvate.
The proportion depends on the substrate delivery, hormone levels (mainly insulin) cardiac work load and perfusion. Different substrate utilization is observed in normal heart in fasting and postprandial stage. FFA are preferred substrate and account for up to 70% of cardiac energy metabolism -in fasting condition, in terms of normal oxygen supply ( Figure 3B ). The carbohydrate (glucose and pyruvate) metabolism reaches only 30% of cardiac muscle demand. The uptake of carbohydrates in fasting stage is generally low, but can be variable and heterogeneous ( Figure   3A ). On the contrary: in postprandial state glucose is a preferred energy source, while fatty acid oxidation is suppressed (Figure 4 ).
Understanding those physiological changes in cardiac metabolism is crucial for proper metabolic 18F-FDG PET study interpretation.
The lack of FDG uptake is suggesting not only the presence of non viable (scar tissue) but also utilization of substrates other than glucose. Therefore the perfusion and FDG metabolic study must be interpreted together. 
Ischemia, hibernation
In the first line cardiac metabolic response to the acute disturbance such as ischemia is to switch myocardial substrate use from FFA to oxidation of glucose, lactate and glycogen, to maintain sufficient fuel supply during increased workload.
Therefore on PET scan acquired in the fasting condition, glucose is preferentially accumulated in ischemic myocardium, and appears as a "hot spot" due to preferential FFA utilization by the rest of normal, non-ischemic myocardium ( Figure 2B ). Myocardial uptake of 18F-FDG is reflecting not only aerobic but also anaerobic glycolytic flux [6] . In normally functioning myocardium all available substrates for energy production are metabolized via oxygen dependent pathways. Only the hypoperfused myocardium is forced to produce energy via non oxidative metabolism. Therefore two cardiac FDG PET study protocols should be considered:
Analysis of cardiac FDG uptake in fasting stage (fasting protocol)
should be performed if acute ischemia is suspected. This protocol is preferred also for detection of metabolic changes due to prior ischemia in myocardium with apparent normal contractile function (metabolic memory phenomenon, after stress inducted ischemia).
Assessment of cardiac viability while myocardial hibernation is suspected, demands to force the myocardium for primarily glucose utilization and registration of cardiac images in postprandial stage.
Thus, to identify viable myocardium in mechanical dysfunctioning areas glucose loading protocols are preferred, because viable cells will accumulate preferentially 18F-FDG, whereas necrotic (scar) tissue will not show the deoxyglucose uptake ( Figure 5 ).
The following example present typical for hibernation metabolic and perfusion uptake pattern -99mTc-MIBI SPECT/ 18FDG PET mismatch.
Case 66-years-old male who has a history of coronary artery disease, status post myocardial infarction involving the inferior and infero-lateral wall ( Figure 6 ).
SPECT Findings
The dipiridamole-stress 99mTc-MIBI examination revealed severe perfusion defect in apical, distal segments of anterior wall, in inferior, infero-lateral and infero-septal wall. The defects in apical and anterior wall region show partial reversibility. Some border reversibility at rest is seen around the fixed defect in inferior and infero-lateral wall. The extent of the stress defect is calculated as 58 percent of the left ventricle, the rest perfusion defect is covering 43% of the left ventricle.
SPECT Conclusions
The rest and stress SPECT study revealed the transmural scar involving the apical, inferior, infero-lateral and infero-septal wall with borderline ischemia. Evaluation of myocardial viability is requested (Figure 7 ).
18FDG-PET findings
There is slight inhomogenous, glucose metabolism seen in the whole left ventricular muscle.
Impression
There is viable, hibernated muscle present in the area matching the resting SPECT perfusion defect. The normal perfused myocardium shows glucose uptake similar to the hibernated area. The result of the PET/SPECT study reflex the muscle with preserved viability but compromised (Figure 8 ).
Discussion
Assessment of cardiac viability while myocardial hibernation is suspected, demands to force the myocardium for primarily glucose utilization and registration of cardiac images in postprandial stage. To identify viable myocardium in mechanical dysfunctioning areas glucose loading protocols are preferred, because viable 
Dilated cardiomyopathy and left ventricular hypertrophy
The cardiac hypertrophy or dilated cardiomyopathy are chronic diseases in which the cardiac metabolic changes occur at a transcriptional level. The genetic profile of the injured heart is switching for adaptation to a "fetal-like" profile that favors glucose over the FFA [7] (Figure 9 ). The current works are carried on the investigation of the connection between the cardiac hypertrophy and FFA oxidation impairment. It was confirmed that the activity of the process of myocardial FFA oxidation is an independent predictor of left ventricular mass in hypertrophy [8] . Not only the FDG-PET study, but also other radiopharmaceuticals allow for FFA oxidation measurements. The PET study with the palmitate -a long-chain fatty acid labeled with 11C is directly reflecting the activity of the FFA beta-oxidation. Studies on glucose and palmitate kinetics have shown that FFA uptake and metabolism is lower in cardiomyopatic patients than in controls [9] . The severity of this metabolic disturbance correlates good with the patient's clinical condition. and non-diabetic patients, FFA utilization is responsible for 70% MVO2, and glucose for the rest 30% [10] . The normal cardiac ability to choose the substrates for energy production in cases of diabetes mellitus is impaired. In consequence, the diabetic heart in terms of increased myocardial work (e.g. stress) is unable increase glucose uptake and metabolism to maintain the adequate MVO2 , this causes the higher sensitivity to ischemia (Figure 10,   11 ). Additionally the increased myocardial lipid accumulation may lead to cardiac cells injury -in consequence the apoptosis and electrical instability [11] . Increased body mass index (BMI) also 
Glucose load protocols
There is no standard protocol for forced cardiac glucose uptake. The main goal is to shift cardiac metabolism to glucose utilization, by increasing the blood glucose level which is stimulating the endogenous insulin response and increase the intracellular glucose transport. The intravenous or oral glucose load may be used, the other possible choice is oral acipimox administration. The main goal of patient preparation, independent from the protocol www.nmr.viamedica.pl Małgorzata Kobylecka et al., Myocardial viability assessment in 18FDG PET/CT study Review -is to push the myocardium for preferential glucose utilization. All the protocols require keeping the patient fasting for at least 6 hr, This is necessary to induce proper endogenous insulin response.
Shorter fasting time could depress this physiological process.
A sample protocols are given below:
Oral glucose
This protocol is preferred in most nuclear medicine units because of its simplicity. The patient must be nondiabetic, with good blood glucose control, after at least 6 hours of fasting. For optimal FDG cardiac uptake the blood glucose has to be held at 100 to 140 mg/ml at FDG injection time. The protocol starts with oral glucose load of 25 to 100 g. The blood glucose has to be measured periodically during the next 60 min. The blood glucose level must fall sufficiently at 60 min after oral glucose administration. If the blood glucose ranges between 100-140 mg/dL, the FDG can be injected. The protocol is easy to implement and easy to perform in routine practice, but often needs some modification dependent on the blood glucose level. If the blood glucose rises over 140 mg/dl (140-160 mg/dL) the 2 U of regular insulin has to be additionally injected. The injected insulin amount should be further increased if the blood glucose reaches higher level. The amount of 1-2 U insulin should be injected on every 10 mg/dL over the maximal allowed (140 mg/dL) blood glucose level [13] .
Intravenous glucose
The intravenous glucose administration is more complicated but it avoids the problems with variable gastrointestinal glucose absorption time. This protocol can be used if the patient is non diabetic and his/her fasting blood glucose is less than 110 mg/mL.
The most convenient way is to use the hyperinsulinemic euglyce- Still, despite the optimization, there is up to 10-15% of uninterpretable cases noted [6] .
Hyperinsulinemic-euglycemic clamp
This protocol is effective both in diabetes and patients with normal glucose tolerance. It is used mostly in investigational studies, for exclusion of differences in glucose intestinal absorption. The protocol starts with the blood glucose level estimation, repetitive measurements should be carried on every 15 min until 18FDG injection. The insulin should be injected in declining infusion rates-starting with 0.16 U/min/kg for 4 minutes, than 0.08 U/min/kg for next 3 minutes and 0.04 U/min/kg at 8th minute. Co-infusion of 20% dextrose should be carried on in order to achieve the constant, euglycemic blood glucose concentration. The 18FDG is injected when blood glucose reach the range 80-110 mg/dl and remains constant for at least approximately 30 min. For the best image quality, the insulin and dextrose infusion should be maintained for another 30 min [13] .
Glucose-insulin infusion
The following protocol is often used both in diabetes and non-diabetes patients, it is less time consuming and less complicated than hyperinsulinemic euglycemic clamp. The protocol starts with the priming regular insulin injection -6 (10) U, if the initial blood glucose level exceed 100 (140) mg/dl. The following co-infusions: insulin (100 U diluted in 500 ml 0.9% saline solution) at a rate of 1,2 ml/kg/min and 20% dextrose at a rate 1,8 ml/kg/h should be carried on for next 60 min. If the blood glucose level is maintained in the range of 80-140 mg/dl, the 18FDG should be injected at 30 min [14] .
Acipimox oral administration
Oral acipimox administration inhibits the peripherial lipolysis and thus decreases free fatty acids plasma level. The lack of this energetic substrate is causing the preferential glucose utilization by the myocardium (glucose switch). The usual protocol indicate the oral 250 mg acipimox administration 90 to 60 min prior to 18F-FDG injection, after the overnight fasting [4] . Some protocols include additional carbohydrate-protein-rich meal after acipimox administration.
The more detailed description of the mentioned above protocols are described in guidelines published by the American Society of Nuclear Cardiology and the Society of Nuclear Medicine [15] .
PET imaging has proved its accuracy and reproducibi lity for myocardial ischemia and viability assessment. However 
